Join the Oncology Voice Network. Join for Free
Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
immuno-oncology mechanistic models tumor vs. immune system systems pharmacology pharmacokinetics pharmacodynamics molecular and cellular biomarkers

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology


Share This Article


Summary

  • There has been significant growth in the development of immuno-modulating pharmacological treatments for various cancers following the approval of the first immune checkpoint inhibitor.
  • Challenges in immuno-oncology (IO) drug development are complex and span from the discovery phase to late-stage clinical testing and regulatory approval.
  • In the preclinical setting:
    • Numerous potential drug targets around immune checkpoints.
    • Expanding list of immuno-modulatory forces in the tumor microenvironment, presenting new IO drug targets.
    • Emergence of exploratory biomarkers.
    • Potential of combination therapies necessitating quantitative, mechanistic systems models.
  • In the clinical setting:
    • Qualification of surrogate biomarkers predictive of IO treatment efficacy or outcomes.
    • Optimization of IO trial design.
  • The mini-review highlights the evolution and current state of quantitative systems models that describe the interplay between the tumor and the immune system.
  • It also discusses the integration of these models with quantitative pharmacology models of IO-modulating agents as tools to address the challenges in IO drug development.

Immunotherapy of cancer has had a long history of development, starting from pioneering efforts in using coley toxins to treat patients—a therapeutic approach named after Dr. William Coley. Even though these earlier efforts never turned into a standard treatment, further investigations on the relationships between tumor cells and the immune system led to discoveries which unveiled fundamental principles underlying cancer progression, such as immune surveillance, cancer dormancy, cancer immuno-editing, and the cancer immunity cycle.

These discoveries were foundational for clinical successes and corresponding regulatory approvals in recent years, of therapies targeting the CTLA-4, PD-1, and PD-L1 immune checkpoints. In the wake of these successes, there has been an explosion in the development of immuno-modulating, anti-cancer pharmacological modalities, leading to the initiation of, literally, thousands of clinical trials. However, from the discovery phase to late-stage clinical testing and regulatory approval, challenges in the development of immuno-oncology (IO) drugs are multi-fold and complex, with related complexities in the design of clinical trials; if unaddressed, these may lead to a decreased probability of success...

 

Click for Source
immuno-oncology, mechanistic models, tumor vs. immune system, systems pharmacology, pharmacokinetics, pharmacodynamics, molecular and cellular biomarkers

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Quantitative Translation in Immuno-Oncology Research and Development
OVN Avatar Dean Bottino, Rachael Liu, Hojjat Bazzazi, Karthik Venkatakrishnan

Quantitative Translation in Immuno-Oncology Research and Development

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Explore OVN